

# Jason R Pantarotto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6224196/publications.pdf>

Version: 2024-02-01

27  
papers

1,163  
citations

840585

11  
h-index

642610

23  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1642  
citing authors

#	ARTICLE	IF	CITATIONS
1	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncology</i> , The, 2017, 18, 1116-1125.	5.1	415
2	Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1316-1325.	0.8	336
3	Upper abdominal normal organ contouring guidelines and atlas: A Radiation Therapy Oncology Group consensus. <i>Practical Radiation Oncology</i> , 2014, 4, 82-89.	1.1	103
4	Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy. <i>BJU International</i> , 2007, 99, 564-569.	1.3	61
5	Motion Analysis of 100 Mediastinal Lymph Nodes: Potential Pitfalls in Treatment Planning and Adaptive Strategies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1092-1099.	0.4	59
6	Pretreatment [18F]-fluoro-2-deoxy-glucose Positron Emission Tomography Maximum Standardized Uptake Value as Predictor of Distant Metastasis in Early-Stage Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy: Rethinking the Role of Positron Emission Tomography in Personalizing Treatment Based on Risk Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 312-318.	0.4	35
7	Role of Adaptive Radiotherapy During Concomitant Chemoradiotherapy for Lung Cancer: Analysis of Data From a Prospective Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1092-1097.	0.4	32
8	Clinical Specialist Radiation Therapist in Palliative Radiation Therapy: Report of an Orientation, Training, and Support Program. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, 543-550.	0.2	16
9	Clinical use of a novel in vivo 4D monitoring system for simultaneous patient motion and dose measurements. <i>Radiotherapy and Oncology</i> , 2012, 102, 290-296.	0.3	15
10	Treatment of metastatic liver tumors using stereotactic ablative radiotherapy. <i>World Journal of Radiology</i> , 2014, 6, 18.	0.5	15
11	Prognostic Factors in the Radical Nonsurgical Treatment of Stage IIIB Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 237-243.	1.1	13
12	Quantitative texture analysis on pre-treatment computed tomography predicts local recurrence in stage I non-small cell lung cancer following stereotactic radiation therapy. <i>Quantitative Imaging in Medicine and Surgery</i> , 2017, 7, 614-622.	1.1	12
13	Impact of Patient Selection, Disease Progression, and Adverse Events on Esophageal Cancer Outcomes After Trimodality Therapy. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1659-1666.	0.7	10
14	Inferring Positions of Tumor and Nodes in Stage III Lung Cancer From Multiple Anatomical Surrogates Using Four-Dimensional Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1553-1560.	0.4	8
15	Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists. <i>Lung Cancer</i> , 2016, 94, 74-80.	0.9	7
16	Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT). <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 28-33.	0.9	7
17	Radical Treatment of Stage II Non-Small-Cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes. <i>Clinical Lung Cancer</i> , 2018, 19, e11-e18.	1.1	6
18	Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 37-41.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Validating impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy. <i>Thoracic Cancer</i> , 2021, 12, 201-209.	0.8	3
20	Adrenal oligometastasis cured with stereotactic ablative radiotherapy. <i>Radiology Case Reports</i> , 2020, 15, 2266-2270.	0.2	2
21	A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases. <i>Cureus</i> , 2019, 11, e6394.	0.2	2
22	Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastases. <i>Journal of Neuro-Oncology</i> , 2016, 128, 431-436.	1.4	1
23	Lung cancer diagnosis transformation: Aligning the people, processes, and technology sides of the learning system.. <i>Journal of Clinical Oncology</i> , 2016, 34, 50-50.	0.8	1
24	Radiation oncologist consultations prior to prostatectomy in Ontario, Canada: Disparities and opportunities.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17052-e17052.	0.8	0
25	Phase II study of neoadjuvant irinotecan, capecitabine, oxaliplatin (IXO) followed by chemoradiotherapy (CRT) using concurrent capecitabine for resectable locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14571-e14571.	0.8	0
26	Stage II non-small cell lung cancer treated with nonsurgical approaches.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18507-e18507.	0.8	0
27	Cancer Clinic Redesign: Opportunities for Resource Optimization. <i>Current Oncology</i> , 2022, 29, 3983-3995.	0.9	0